Founded in the Tibet Autonomous Region on July 14, 1999traded on the Shanghai Stock Exchange on July 21, 1999, Tibet Nordikon Pharmaceutical Co., Ltd. is the first high-tech pharmaceutical listed enterprise in the Tibet Autonomous Region. Its stock name is Tibet Pharmaceutical,its stock code is 600211. Since its establishment, the company has been recognized as a national high-tech enterprisea key leading enterprise in agricultural industrialization. The companys graphic trademark (Xiangyun Map) has been recognized as a well-known trademark in China by the State Administration for IndustryCommerce.

The company adheres to the concept of "science leads to health,health leads to the future". After more than 20 years of development, it has growna modern pharmaceutical enterprise that integrates researchdevelopment, production,sales. The company has established an enterprise technology center; Three pharmaceutical production bases for biological products, Tibetan medicine products,traditional Chinese medicine products that meet GMP standards; A planting base for Tibetan medicinal materials that meets GAP standards;a vaccine production base. The company currently has nine subsidiary companies in Tibet, Sichuan, Shanghai,other places, including Tibet Nuodikang Pharmaceutical Co., Ltd., Chengdu Nuodikang Biopharmaceutical Co., Ltd.,Shanghai Xinhuo Biotechnology Co., Ltd.

The companys products cover the fields of biopharmaceuticals, Tibetan medicine, traditional Chinese medicine,chemical pharmaceuticals. The core products include "Xinhuosu", a new drug of national biological products, "Nordicam" with Tibetan medicine Rhodiola rosea as raw material,"Imdor", an international first-line drug for cardiovascular diseases; In addition, the company also has excellent varieties of national level traditional Chinese medicines such as "Snow Mountain Gold Arhat Pain Relieving Coating", "Shiwei Dida Capsule", "Children Shuangqing Granules", etc.

In 2022, the company achieved a revenue of 2.555 billion yuan, a year-on-year increase of 19.45%; The net profit attributable to shareholders of the listed company was 370 million yuan, a year-on-year increase of 76.99%; The net profit attributable to shareholders of the listed company after deducting non recurring gainslosses was 369 million yuan, an increase of 453.58% year-on-year. As of December 31, 2022, the total assets of the company were 4.099 billion yuan.